...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Pharmacy and Therapeutics >Effect of long-acting beta-agonists on the frequency of COPD exacerbations: A meta-analysis
【24h】

Effect of long-acting beta-agonists on the frequency of COPD exacerbations: A meta-analysis

机译：长效β受体激动剂对COPD急性发作频率的影响：一项荟萃分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

What is Known and Objective: Inhaled long-acting beta-agonists have been licensed for the treatment of chronic obstructive pulmonary disease (COPD) since the late 1990s, and they improve lung function and symptoms of dyspnoea. However, the evidence that long-acting beta-agonists alone can reduce the rate of COPD exacerbations is not conclusive. This meta-analysis was performed to evaluate their effect on the frequency of exacerbations. Methods: MEDLINE, EMBASE, CINAHL and the Cochrane trials database were searched for the review. Randomized controlled trials of greater than or equal to 24 weeks' treatment duration comparing long-acting beta-agonists (LABAs) with placebo were reviewed. Studies were pooled to yield odds ratios (ORs) with 95% confidence intervals (CIs). Results and Discussion: Seventeen randomized controlled trials (11871 randomized subjects) met the inclusion criteria and were selected for analysis. Salmeterol, formoterol and indacaterol significantly reduced COPD exacerbations compared with placebo. Salmeterol significantly reduced COPD exacerbations with both study arms exposed or not exposed to inhaled corticosteroids (ICS). The summary ORs were 0.79 (95% CI: 0.67-0.92; P < 0.01) and 0.80 (95% CI: 0.65-0.99; P = 0.04), respectively. However, when both arms were not exposed to ICS, there was no significant reduction in exacerbations with formoterol compared with placebo. The 'summary OR was 0.93 (95% CI: 0.75-1.15; P = 0.50). What is New and Conclusion: Long-acting beta-agonists reduce the frequency of COPD exacerbations. Salmeterol, formoterol and indacaterol significantly reduced COPD exacerbations compared with placebo. Salmeterol but not formoterol decreased exacerbations significantly in the absence of ICS.
机译：已知和目的：自1990年代后期以来，吸入型长效β受体激动剂已获许可用于治疗慢性阻塞性肺疾病（COPD），它们可改善肺功能和呼吸困难症状。但是，仅长效β-激动剂可以降低COPD恶化率的证据尚无定论。进行这项荟萃分析，以评估其对病情加重的影响。方法：检索MEDLINE，EMBASE，CINAHL和Cochrane试验数据库以进行评价。回顾了比较长效β-激动剂（LABA）和安慰剂的治疗期大于或等于24周的随机对照试验。汇总研究以产生具有95％置信区间（CI）的优势比（OR）。结果与讨论：符合纳入标准的17项随机对照试验（11871例随机受试者）被选择进行分析。与安慰剂相比，沙美特罗，福莫特罗和茚达特罗显着降低了COPD恶化。沙美特罗可显着降低COPD恶化，无论是研究手臂接触还是未接触吸入皮质类固醇（ICS）。总OR分别为0.79（95％CI：0.67-0.92; P <0.01）和0.80（95％CI：0.65-0.99; P = 0.04）。但是，当两臂均未暴露于ICS时，与安慰剂相比，福莫特罗的急性加重没有明显减少。 '总OR为0.93（95％CI：0.75-1.15; P = 0.50）。新发现和结论：长效β激动剂可减少COPD恶化的频率。与安慰剂相比，沙美特罗，福莫特罗和茚达特罗显着降低了COPD恶化。在没有ICS的情况下，沙美特罗而非福莫特罗可显着降低病情恶化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号